Lupin soars on getting USFDA’s tentative approval for Sugammadex Injection
Lupin is currently trading at Rs. 2349.00, up by 36.30 points or 1.57% from its previous closing of Rs. 2312.70 on the BSE.
The scrip opened at Rs. 2333.25 and has touched a high and low of Rs. 2359.90 and Rs. 2312.55 respectively. So far 2458 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2376.00 on 11-Mar-2026 and a 52 week low of Rs. 1774.00 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs. 2369.15 and Rs. 2295.70 respectively. The current market cap of the company is Rs. 107437.09 crore.
The promoters holding in the company stood at 46.89%, while Institutions and Non-Institutions held 47.07% and 6.03% respectively.
Lupin has received tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application for Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vial.
The USFDA has tentatively approved Lupin’s Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vial as bioequivalent to Merck’s Bridion Injection for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged 2 years and older undergoing surgery.
